COO vs. MDLN: Cooper vs. Medline Stock Comparison

Company Profile

Cooper (COO) and Medline (MDLN) are both classified in the Health Care Supplies sub-industry within the broader Health Care Equipment & Supplies industry, placing them in the closest GICS peer bucket.

Cooper (COO) has been public since January 21, 1983, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Cooper (COO) has a non-negative beta of 0.79.

Risk-Adjusted Performance

Risk-Return Positioning

Both COO and MDLN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Both Cooper (COO) at 6.84% and Medline (MDLN) at 4.85% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Cooper (COO) at 13.46% retains a top-quartile share of revenue as profit, ahead of Medline (MDLN) at 1.85%, which keeps about the industry-typical share.

Cooper (COO) at 20.82% operates in the top operating margin quartile, ahead of Medline (MDLN) at 5.22%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Cooper (COO) reports revenue growth of 5.06%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Medline (MDLN) at 117.38% clears its industry range for EPS growth, a much stronger earnings trajectory than Cooper (COO) at -4.59%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Medline (MDLN) at 4.04 carries current ratio above its industry’s typical mid-range, while Cooper (COO) at 1.22 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Both Cooper (COO) at 0.34 and Medline (MDLN) at 0.65 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Cooper (COO) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Cooper (COO) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Cooper (COO) at 21.43 is near its industry’s usual P/E ratio, while Medline (MDLN) at 90.09 sits above its peer range — an unusually expensive price for MDLN’s trailing earnings.

On P/S ratio, both Cooper (COO) at 2.80 and Medline (MDLN) at 1.70 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Cooper (COO) at 1.42 sits in the lower P/B ratio quartile against book while Medline (MDLN) at 2.95 is valued near its industry’s middle — COO is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics